TCM
PTGX icon

Triumph Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Triumph Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9K Hold
18
– – ﹤0.01% 1544
2025
Q4 		$1.57K Buy
+18
New +$1.47K ﹤0.01% 1502

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Triumph Capital Management's PTGX Position: Q1 2026 in Review

Triumph Capital Management held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 18 shares worth $1.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

Triumph Capital Management first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Triumph Capital Management held 18 shares of Protagonist Therapeutics worth $1.9K as of Q1 2026.
  • Triumph Capital Management left its Protagonist Therapeutics share count unchanged in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Triumph Capital Management's portfolio in Q1 2026, its #1544 holding.
  • Triumph Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.